• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu
  • the mission ahead

    To develop therapies through knowledge, experience and insight that elevate the human condition.

    About PropellaRx

upwardly innovative

Propella develops innovative, best-in-class therapeutics with an eye toward mitigated development risk.  We use proven science, a novel approach, and development insight to produce products that are smarter, safer, and more effective.

We are a privately held development-stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action.  Our lead product candidate, PRL-02, is currently in a phase 1 dose-escalation study for metastatic prostate cancer.  Topical CGS-200-5 has been developed for the management of knee pain due to osteoarthritis (OA) and is Phase 3 ready, having successfully completed a predictive Phase 2 study.  We are actively advancing additional oncology therapies through our discovery process.

Both PRL-02 and CGS-200-5 product candidates are covered by issued US patents that are wholly owned by Propella.

  • our history
  • management
  • board of directors
  • advisors
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top